#VisualAbstract: Higher metastatic lymph node burden is associated with worse overall survival in Merkel cell carcinoma

byTeddy Guo

March 4, 2021

in StudyGraphics

Reading Time: 1 min read

Type 1 spinal muscular atrophy improved with risdiplam

RelatedReports

StudyGraphics

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

April 26, 2022

StudyGraphics

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

April 12, 2022

StudyGraphics

#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas

March 22, 2022

StudyGraphics

#VisualAbstract: Differences in Merkel cell carcinoma recurrence and survival rates stratified by cancer stage

March 15, 2022

$#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma$

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]

Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract: Higher metastatic lymph node burden is associated with worse overall survival in Merkel cell carcinoma

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas

Type 1 spinal muscular atrophy improved with risdiplam

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

RelatedReports

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

#VisualAbstract: Solid organ transplant recipients are at an increased risk of developing non-melanoma skin cancers

#VisualAbstract: Immunocompromised individuals may be at an increased risk of metastses with cutaneous squamous cell carcinomas

#VisualAbstract: Differences in Merkel cell carcinoma recurrence and survival rates stratified by cancer stage

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get 2MM+ Premium Access

Recent Reports

#VisualAbstract: Higher metastatic lymph node burden is associated with worse overall survival in Merkel cell carcinoma

RELATED REPORTS

Type 1 spinal muscular atrophy improved with risdiplam

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get 2MM+ Premium Access

Recent Reports